BRPI0614566A2 - derivados de 2-oxo azepan subtituìdos por fluoro - Google Patents

derivados de 2-oxo azepan subtituìdos por fluoro

Info

Publication number
BRPI0614566A2
BRPI0614566A2 BRPI0614566-3A BRPI0614566A BRPI0614566A2 BR PI0614566 A2 BRPI0614566 A2 BR PI0614566A2 BR PI0614566 A BRPI0614566 A BR PI0614566A BR PI0614566 A2 BRPI0614566 A2 BR PI0614566A2
Authority
BR
Brazil
Prior art keywords
substituted
fluoro
halogen
lower alkyl
heteroaryl
Prior art date
Application number
BRPI0614566-3A
Other languages
English (en)
Inventor
Alexandre Flohr
Guido Galley
Roland Jakob-Roetne
Eric Argirios Kitas
Wolfgang Wostl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0614566A2 publication Critical patent/BRPI0614566A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADOS DE 2-OXO AZEPAN SUBTITUìDOS POR FLUORO. Trata-se de compostos da fórmula geral (I), onde R^ 1^ é alquila inferior substituida por halogênio, ou é arila ou heteroarila, não-substituida ou substituida por halogênio; R^ 2^ é heterocicloalquila, arila ou heteroarila, que são não-substituidas ou substituidas por um ou mais substituintes, selecionados do grupo que consiste em halogênio, alquilóxi interior, alquila inferior substituida por halogênio, O-alquila inferior substituida por halogênio ou são substituidas por C(O)NR"2, (CR2 22)2 m2C(O)R', heteroarila ou S(O)2 22-alquila inferior; R^ 3^/R^ 3'^, R^ 4^/R^ 4^ e R^ 5^/R^ 5^ são independentemente um do outro hidrogênio ou fluoro, onde pelo menos um entre R^ 4^/R^ 4'^ ou sempre é fluoro; R' é arila ou hidróxi; R" é hidrogênio, cicloalquila ou é heterocicloalquila; R é hidrogênio ou alquila inferior; m é 0,1, 2 ou 3; e de sais de adição de ácido farmaceuticamente aceitáveis, enantiómeros opticamente puros, racematos ou misturas diastereoméricas destes. Foi verificado que os compostos da fórmula geral (1) são inibidores de y-secretase e os compostos relacionados podem ser úteis no tratamento de doença de Alzheimer ou cânceres comuns que incluem, porém sem caráter limitativo, carcinomas cervicais e carcinomas de mama e malignidades do sistema hematopoiético.
BRPI0614566-3A 2005-08-12 2006-08-02 derivados de 2-oxo azepan subtituìdos por fluoro BRPI0614566A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107455 2005-08-12
PCT/EP2006/064935 WO2007020190A1 (en) 2005-08-12 2006-08-02 Fluoro substituted 2-oxo azepan derivatives

Publications (1)

Publication Number Publication Date
BRPI0614566A2 true BRPI0614566A2 (pt) 2009-08-04

Family

ID=37102441

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0614566-3A BRPI0614566A2 (pt) 2005-08-12 2006-08-02 derivados de 2-oxo azepan subtituìdos por fluoro

Country Status (19)

Country Link
US (1) US7501406B2 (pt)
EP (1) EP1915345B1 (pt)
JP (1) JP4885958B2 (pt)
KR (1) KR101020397B1 (pt)
CN (1) CN101238106B (pt)
AR (1) AR055370A1 (pt)
AT (1) ATE492536T1 (pt)
AU (1) AU2006281493A1 (pt)
BR (1) BRPI0614566A2 (pt)
CA (1) CA2619223A1 (pt)
DE (1) DE602006019103D1 (pt)
ES (1) ES2355581T3 (pt)
IL (1) IL189026A0 (pt)
MX (1) MX2008001833A (pt)
NO (1) NO20080498L (pt)
RU (1) RU2419611C2 (pt)
TW (1) TWI325421B (pt)
WO (1) WO2007020190A1 (pt)
ZA (1) ZA200800930B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667802A1 (en) * 2006-11-03 2008-05-29 Northwestern University Multiple sclerosis therapy
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
GB201009603D0 (en) 2010-06-08 2010-07-21 Cambridge Entpr Ltd Anti-inflammatory agent
WO2012014127A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001253108A1 (en) * 2000-04-03 2001-10-15 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of a-beta protein production
ZA200507806B (en) * 2003-03-24 2007-03-28 Actimis Pharmaceuticals Inc 2-phenoxy- and 2-enysulfomamide derivatives with CCR3 antagonistic acitivity for the treatment of asthma and other inflammatory or immunolgical disorders
RU2364587C2 (ru) * 2003-10-29 2009-08-20 Элан Фармасьютикалз, Инк. N-замещенные бензолсульфонамиды
CA2573372A1 (en) * 2004-07-13 2006-01-19 F. Hoffmann-La Roche Ag Sulfonamide derivatives

Also Published As

Publication number Publication date
ZA200800930B (en) 2009-02-25
KR20080027936A (ko) 2008-03-28
US20070037789A1 (en) 2007-02-15
AU2006281493A1 (en) 2007-02-22
JP2009504600A (ja) 2009-02-05
TW200734308A (en) 2007-09-16
EP1915345A1 (en) 2008-04-30
EP1915345B1 (en) 2010-12-22
IL189026A0 (en) 2008-08-07
CN101238106B (zh) 2011-02-16
KR101020397B1 (ko) 2011-03-08
RU2419611C2 (ru) 2011-05-27
TWI325421B (en) 2010-06-01
AR055370A1 (es) 2007-08-22
ATE492536T1 (de) 2011-01-15
CA2619223A1 (en) 2007-02-22
US7501406B2 (en) 2009-03-10
WO2007020190A1 (en) 2007-02-22
DE602006019103D1 (de) 2011-02-03
RU2008103452A (ru) 2009-09-20
JP4885958B2 (ja) 2012-02-29
NO20080498L (no) 2008-03-07
MX2008001833A (es) 2008-04-09
CN101238106A (zh) 2008-08-06
ES2355581T3 (es) 2011-03-29

Similar Documents

Publication Publication Date Title
MXPA04003007A (es) Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades.
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
PE20080670A1 (es) COMPUESTOS DE 4-METILPIRIDOPIRIMIDINONA COMO INHIBIDORES DE LA FOSFOINOSITIDO 3-QUINASA ALFA (PI3-Ka)
MA27734A1 (fr) DERIVES HEXAHYDROPYRAZINO [1,2-a]PYRIMIDINE-4,7-DIONE SUBSTITUES SUR L'AZOTE, METHODE POUR LEUR PRODUCTION ET LEUR UTILISATION EN TANT QUE MEDICAMENTS
MA27654A1 (fr) DERIVES HEXAHYDROPYRAZINO [1,2-a]-4,7-DIONE SUBSTITUES, METHODE POUR LEUR PRODUCTION ET LEUR UTILISATION EN TANT QUE MEDICAMENTS
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
MA29539B1 (fr) Procedes de production de derives phenoliques 4-biphenylylazetidin -2-one
BRPI0614566A2 (pt) derivados de 2-oxo azepan subtituìdos por fluoro
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
CO6300861A2 (es) Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos
NO20054095L (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater
TW200740795A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
IL186777A0 (en) (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor
ES2776680T3 (es) Compuestos derivados de heterocicloalquilo como inhibidores selectivos de histona desacetilasa y composiciones farmacéuticas que los comprenden
BRPI0409739A (pt) composto, composição farmacêutica, uso de composto, e, método para o tratamento de uma doença ou de um distúrbio
PE20090372A1 (es) Derivados de indolinonas como inhibidores de quinasas especificas del ciclo celular
CN112442049A (zh) 作为Wee1抑制剂的嘧啶衍生物
DK1745010T3 (da) Substituerede cyklohexyl-1,4-diaminderivater
PE20060103A1 (es) Nuevas 5-acilindolinonas con contenido en cicloalquilo y su preparacion como medicamento
PE20050336A1 (es) Compuestos triciclicos como inhibidores de la proteina farnesil transferasa
ES2776359T3 (es) Quinazolin-thf-aminas halogenadas como inhibidores de PDE1
WO2015009742A2 (en) Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
AR036735A1 (es) Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina
JP2018536652A5 (pt)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2214 DE 11/06/2013.